drugset
drugset / Trial / NCT03495817

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

NCT03495817 ↗

Phase 2 Completed 31 enrolled Aclaris Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.

Timeline

Start
2018-03-22
Primary completion
2019-10-15
Completion
2019-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IFIDANCITINIB Small molecule 0.46 % Topical

Indications

androgenetic alopecia